Germline CDH1 Variants and Lifetime Cancer Risk

Author:

Ryan Carrie E.1,Fasaye Grace-Ann2,Gallanis Amber F.1,Gamble Lauren A.1,McClelland Paul H.1,Duemler Anna2,Samaranayake Sarah G.1,Blakely Andrew M.1,Drogan Christine M.3,Kingham Kerry4,Patel Devanshi5,Rodgers-Fouche Linda5,Siegel Ava6,Kupfer Sonia S.3,Ford James M.7,Chung Daniel C.56,Dowty James G.8,Sampson Joshua9,Davis Jeremy L.1

Affiliation:

1. Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

2. Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

3. Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois

4. Cancer Genetics and Genomics, Stanford University, Stanford, California

5. Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston

6. Division of Gastroenterology, Massachusetts General Hospital, Boston

7. Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California

8. Centre for Epidemiology and Biostatistics, University of Melbourne, Melbourne, Victoria, Australia

9. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Abstract

ImportanceApproximately 1% to 3% of gastric cancers and 5% of lobular breast cancers are hereditary. Loss of function CDH1 gene variants are the most common gene variants associated with hereditary diffuse gastric cancer and lobular breast cancer. Previously, the lifetime risk of gastric cancer was estimated to be approximately 25% to 83% and for breast cancer it was estimated to be approximately 39% to 55% in individuals with loss of function CDH1 gene variants.ObjectiveTo describe gastric and breast cancer risk estimates for individuals with CDH1 variants.Design, Setting, and ParticipantsMulticenter, retrospective cohort and modeling study of 213 families from North America with a CDH1 pathogenic or likely pathogenic (P/LP) variant in 1 or more family members conducted between January 2021 and August 2022.Main Outcomes and MeasuresHazard ratios (HRs), defined as risk in variant carriers relative to noncarriers, were estimated for each cancer type and used to calculate cumulative risks and risks per decade of life up to age 80 years.ResultsA total of 7323 individuals from 213 families were studied, including 883 with a CDH1 P/LP variant (median proband age, 53 years [IQR, 42-62]; 4% Asian; 4% Hispanic; 85% non-Hispanic White; 50% female). In individuals with a CDH1 P/LP variant, the prevalence of gastric cancer was 13.9% (123/883) and the prevalence of breast cancer among female carriers was 26.3% (144/547). The estimated HR for advanced gastric cancer was 33.5 (95% CI, 9.8-112) at age 30 years and 3.5 (95% CI, 0.4-30.3) at age 70 years. The lifetime cumulative risk of advanced gastric cancer in male and female carriers was 10.3% (95% CI, 6%-23.6%) and 6.5% (95% CI, 3.8%-15.1%), respectively. Gastric cancer risk estimates based on family history indicated that a carrier with 3 affected first-degree relatives had a penetrance of approximately 38% (95% CI, 25%-64%). The HR for breast cancer among female carriers was 5.7 (95% CI, 2.5-13.2) at age 30 years and 3.9 (95% CI, 1.1-13.7) at age 70 years. The lifetime cumulative risk of breast cancer among female carriers was 36.8% (95% CI, 25.7%-62.9%).Conclusions and RelevanceAmong families from North America with germline CDH1 P/LP variants, the cumulative risk of gastric cancer was 7% to 10%, which was lower than previously described, and the cumulative risk of breast cancer among female carriers was 37%, which was similar to prior estimates. These findings inform current management of individuals with germline CDH1 variants.

Publisher

American Medical Association (AMA)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3